Our study demonstrates that obtaining high rates of treatment CHIR-99021 supplier completion (through strict adherence and adequate management of adverse events) results in SVR rates in routine clinical care that are similar to those reported in randomized clinical trials. It should be emphasized that treatment by experienced physicians in routine clinical practice is safe and effective. Special support might be needed for minority groups, just as for difficult-to-treat patients, such as intravenous drug users. Adequate selection of candidates for treatment is very important for obtaining substantial SVR rates. Ezequiel

Ridruejo M.D.*, Raúl Adrover M.D.†, Daniel Cocozzella M.D.†, María Virgina Reggiardo M.D.‡, Nora Fernández M.D.§, * Hepatology Section, Department of Medicine, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno, Buenos Aires, Argentina, † Centro de Hepatología, La Plata, Argentina, ‡ Hospital Provincial del Centenario/Sanatorio Americano, Rosario, Argentina, § Hospital Británico, Buenos Aires, Argentina. “
“Liver transplantation is the only established therapy for patients with end-stage liver disease. The procedure is also indicated in fulminant liver failure, metabolic diseases, and hepatocellular carcinoma. Survival after liver transplantation is approximately 75–80% at 3 years. Donor organ shortage is

a major limitation in adult liver transplantation and is responsible for significant mortality and morbidity in patients on the waiting list. Strategies to increase the number of donor organs include the BTK inhibitor use of marginal livers, split liver, and living donors. Life-long immunosuppression is required in these patients. Post-transplant complications include rejection, recurrent disease, opportunistic infections, and

lymphoproliferative disorders, in addition to the risk of extrahepatic malignancy. “
“See article in J. Gastroenterol. Hepatol. 2011; 26: 1630–1637. Hepatocellular carcinoma (HCC) is a global health concern 上海皓元 with a poor prognosis and is the third leading cause of worldwide cancer-related mortality with less than 50% of patients surviving a year following diagnosis.1 The vast majority of patients present with unresectable disease2 and are treated with palliative intent using locoregional or systemic therapies and best supportive care. The natural history and management of HCC are driven in major part by the underlying cirrhosis and liver dysfunction, which are present in the majority of patients diagnosed with this disease. In the current issue of the Journal, Wang et al. report the expression patterns, interactions and potential clinical implications of microRNA-199b (miR-199b) and hypoxia-inducible factor-1α (HIF-1α) in HCC.3 In this multi-faceted study, the authors build a case suggesting that miR-199b plays a growth inhibitory role in hepatocytes, which is downregulated in established HCC.